Bioxyne Secures 1,550kg Import Permits and A$5.1M Orders in Germany

Bioxyne's Entry into the German Medical Cannabis Market

Bioxyne Limited (ASX – BXN) has taken a significant step forward in its international expansion by securing import authorisations from the German government for 1,550 kilograms of medical cannabis products. This regulatory milestone enables Bioxyne to begin exporting its GMP-certified cannabis flower products to Germany, a market known for its stringent pharmaceutical standards and growing demand for medicinal cannabis.

The company’s local German partner has facilitated these import permits, setting the stage for shipments planned between late September and early October 2025. This development follows Bioxyne’s June announcement of a commercial agreement to supply a minimum of A$5.6 million worth of medical cannabis products in the 2026 financial year.

Strong Initial Purchase Orders and Future Outlook

As of early September, Bioxyne has already received purchase orders totaling A$5.1 million from German clients, nearly fulfilling the minimum contracted supply volume. Notably, the company’s partners Farmakem and Adrex have forecasted multiple reorders scheduled for November, January, March, and May, contingent on ongoing import/export permits and market conditions. These reorder forecasts suggest that actual sales could surpass the initial contract value, highlighting promising demand momentum.

Bioxyne’s subsidiary, Breathe Life Sciences (BLS), plays a pivotal role in this expansion. BLS is a GMP-licensed manufacturer and distributor of controlled substances, including medicinal cannabis, MDMA, and psilocybin. With manufacturing and distribution facilities spanning Australia, Japan, the UK, and Europe, BLS provides Bioxyne with a robust operational platform to support international growth.

Strategic Implications and Market Positioning

Germany represents one of Europe’s largest and most regulated medical cannabis markets, making Bioxyne’s entry a noteworthy achievement. The company’s ability to secure import permits and near-term purchase orders underscores its readiness to compete in this complex environment. Moreover, the forecasted reorders indicate that Bioxyne’s products are gaining traction among German healthcare providers and distributors.

Looking ahead, Bioxyne’s success in Germany could serve as a springboard for further European expansion. The company’s diversified portfolio, including novel medicines and active pharmaceutical ingredients, positions it well to capitalize on evolving regulatory frameworks and growing patient demand across multiple jurisdictions.